Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
178.9 USD | +0.53% |
|
+0.50% | -29.12% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 65.08 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.12% | 6.9B | C+ | ||
+75.69% | 12.57B | - | B- | |
-8.98% | 5.69B | C- | ||
+5.35% | 5.04B | D+ | ||
-17.92% | 4.69B | B | ||
+14.80% | 4.18B | - | ||
-18.25% | 3.86B | B- | ||
-22.31% | 2.97B | C | ||
-1.36% | 1.99B | - | ||
+11.62% | 1.81B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PEN Stock
- Ratings Penumbra, Inc.